WQLN

WuXi Biologics is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) that provides end-to-end solutions for biologics discovery, development, and manufacturing. The company offers a comprehensive platform that enables partners to take a biologic from concept to commercialization through its 'Follow-the-Molecule' strategy. WuXi Biologics is renowned for its proprietary technology platforms, such as WuXiBody for bispecific antibodies and WuXian for ADC development. With significant manufacturing capacity across Asia, Europe, and North America, the company supports a vast pipeline of programs ranging from pre-clinical research to large-scale commercial production. Its business model is designed to lower the barriers to entry for biotech innovation while ensuring high-quality, cost-effective delivery of complex therapeutic proteins.